Pyxis Oncology, Inc.
NASDAQ:PYXS
4.28 (USD) • At close November 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 16.146 | 3.42 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.585 | 1.591 | 0.763 | 0.677 | 0.699 | 0.334 | 0.464 | 0.507 | 0.475 | 0.39 | 0.314 | 0.312 | 0 | 0 | 0 | 0.41 | 0 | 0 |
| Gross Profit
| 0 | -0.585 | 14.555 | 2.657 | -0.677 | -0.699 | -0.334 | -0.464 | -0.507 | -0.475 | -0.39 | -0.314 | -0.312 | 0 | 0 | 0 | -0.41 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0.901 | 0.777 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 17.741 | 13.953 | 11.913 | 10.844 | 14.687 | 11.391 | 11.901 | 29.854 | 19.034 | 17.17 | 20.071 | 7.226 | 7.849 | 3.205 | 32.774 | 3.139 | 2.425 | 1.742 | 1.742 |
| General & Administrative Expenses
| 6.013 | 6.079 | 8.247 | 6.16 | 10.667 | 6.73 | 9.053 | 8.119 | 9.359 | 8.556 | 11.318 | 9.2 | 3.772 | 2.736 | 2.955 | 1.44 | 0.767 | 0.82 | 0.82 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 6.013 | 6.079 | 8.247 | 6.16 | 10.667 | 6.73 | 9.053 | 8.119 | 9.359 | 8.556 | 11.318 | 9.2 | 3.772 | 2.736 | 2.955 | 1.44 | 0.767 | 0.82 | 0.82 |
| Other Expenses
| 0 | 0 | 0.799 | 0.576 | 0.598 | 0.564 | 0.038 | 0 | 0 | 0 | 0 | 0 | 0 | 0.181 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 23.754 | 20.032 | 20.16 | 17.004 | 25.354 | 18.121 | 20.954 | 37.973 | 28.393 | 25.726 | 31.389 | 16.426 | 11.621 | 5.941 | 35.729 | 4.579 | 3.192 | 2.562 | 2.562 |
| Operating Income
| -23.754 | -20.032 | -5.605 | -17.767 | -25.354 | -18.121 | -20.954 | -37.973 | -28.393 | -25.726 | -31.389 | -16.426 | -11.621 | -5.941 | -35.729 | -4.579 | -3.192 | -2.562 | -2.562 |
| Operating Income Ratio
| 0 | 0 | -0.347 | -5.195 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 2.551 | 2.731 | 2.349 | 2.17 | 2.305 | 0.564 | 1.711 | 1.872 | 0.719 | 0.164 | 0.009 | -0.41 | -2.56 | -2.211 | -1.1 | 0 | 0.001 | 0.033 | 0.033 |
| Income Before Tax
| -21.203 | -17.301 | -3.256 | -15.597 | -23.049 | -15.901 | -19.243 | -36.101 | -27.674 | -25.562 | -31.38 | -16.829 | -14.175 | -8.146 | -36.825 | -4.579 | -3.191 | -2.529 | -2.529 |
| Income Before Tax Ratio
| 0 | 0 | -0.202 | -4.561 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 1.073 | 3.89 | -0.523 | -1.656 | -1.711 | -58.987 | -0.719 | -0.164 | -0.009 | 42.183 | 2.554 | 4.36 | 2.192 | 0 | -0.001 | 0 | 0 |
| Net Income
| -21.203 | -17.301 | -3.256 | -15.597 | -23.049 | -15.901 | -17.532 | 22.886 | -26.955 | -25.398 | -31.371 | -16.829 | -14.175 | -8.146 | -36.825 | -4.579 | -3.191 | -2.529 | -2.529 |
| Net Income Ratio
| 0 | 0 | -0.202 | -4.561 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.35 | -0.29 | -0.064 | -0.35 | -0.56 | -0.41 | -0.5 | 0.65 | -0.83 | -0.78 | -0.97 | -0.53 | -0.45 | -0.26 | -1.66 | -0.21 | -0.14 | -2.74 | -2.74 |
| EPS Diluted
| -0.35 | -0.29 | -0.064 | -0.35 | -0.56 | -0.41 | -0.5 | 0.65 | -0.83 | -0.78 | -0.97 | -0.53 | -0.45 | -0.26 | -1.66 | -0.21 | -0.14 | -2.74 | -2.74 |
| EBITDA
| -23.754 | -20.032 | -4.489 | -17.004 | -25.354 | -17.597 | -20.764 | -37.781 | -28.193 | -25.567 | -31.231 | -15.858 | -8.902 | -3.563 | -34.516 | -4.409 | -2.923 | -2.547 | -2.547 |
| EBITDA Ratio
| 0 | 0 | -0.278 | -4.972 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |